Tasly Biopharma Raises $84.5 Million in Pre-IPO Round

03:43 EDT 14 Jul 2018 | ChinaBio Today

Tasly Biopharma of Shanghai raised $84.5 million in new capital from a group of investors that included Ally Bridge. The funding is a pre-IPO round as Tasly is planning to list on the Hong Kong Exchange. The investors received a 4.5% stake in Tasly Biopharma, implying a $1.9 billion pre-IPO valuation. Tasly Biopharma is a subsidiary of Tasly Pharma. As a separate part of the transaction, Transgene transferred its half of a China drug JV to Tasly in exchange for $48 million of stock at the same valuation. More details....

Stock Symbols: (SHA: 600535) (P: TNG)

Share this with colleagues:

Original Article: Tasly Biopharma Raises $84.5 Million in Pre-IPO Round


More From BioPortfolio on "Tasly Biopharma Raises $84.5 Million in Pre-IPO Round"

Quick Search


Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...